Dataset Information

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

ABSTRACT: There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.

SUBMITTER: Omata M

PROVIDER: S-EPMC5491694 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Omata Masao M Cheng Ann-Lii AL Kokudo Norihiro N Kudo Masatoshi M Lee Jeong Min JM Jia Jidong J Tateishi Ryosuke R Han Kwang-Hyub KH Chawla Yoghesh K YK Shiina Shuichiro S Jafri Wasim W Payawal Diana Alcantara DA Ohki Takamasa T Ogasawara Sadahisa S Chen Pei-Jer PJ Lesmana Cosmas Rinaldi A CRA Lesmana Laurentius A LA Gani Rino A RA Obi Shuntaro S Dokmeci A Kadir AK Sarin Shiv Kumar SK

Hepatology international 20170615 4

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This late ...[more]

PMID: 28620797

Similar Datasets

Project description:Importance Approximately half of newly-diagnosed hepatocellular carcinoma (HCC) cases in the world occur in China, with hepatitis B virus (HBV) infection being the predominant risk factor. Recently, the guidelines for the management of Chinese HCC patients were updated. Objective The past decade has witnessed a great improvement in the management of hepatocellular carcinoma (HCC). This study reviews the recommendations in the 2019 Chinese guidelines and makes comparison with the practices from the Western world. Evidence Review The updated recommendations on the surveillance, diagnosis, and treatment algorithm of HCC in the 2019 Chinese guidelines were summarized, and comparisons among the updated Chinese guidelines, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) guidelines were made. Findings Besides imaging and pathological diagnoses, novel biomarkers like the seven-micro-RNA panel are advocated for early diagnoses and therapeutic efficacy evaluation in the updated Chinese guidelines. The China liver cancer (CNLC) staging system, proposed in the 2017 guidelines, continues to be the standard model for patient classification, with subsequent modifications and updates being made in treatment allocations. Compared to the Barcelona Clinic Liver Cancer (BCLC) system, the CNLC staging system employs resection, transplantation, and transarterial chemoembolization (TACE) for more progressed HCC. TACE in combination with other regional therapies like ablation or with systemic therapies like sorafenib are also encouraged in select patients in China. The systemic treatments for HCC have evolved considerably since lenvatinib, regorafenib, carbozantinib, ramucirumab and immune checkpoint inhibitors (ICIs)were first prescribed as first-line or second-line agents. Conclusions and Relevances Novel biomarkers, imaging and operative techniques are recommended in the updated Chinese guideline. More aggressive treatment modalities are suggested for more progressed HBV-related HCC in China.

Dataset Information

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Publications

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure